Association of the COVID-19 outbreak with acute stroke care in Switzerland
- PMID: 34894018
- PMCID: PMC9305499
- DOI: 10.1111/ene.15209
Association of the COVID-19 outbreak with acute stroke care in Switzerland
Abstract
Background and purpose: In Switzerland, the COVID-19 incidence during the first pandemic wave was high. Our aim was to assess the association of the outbreak with acute stroke care in Switzerland in spring 2020.
Methods: This was a retrospective analysis based on the Swiss Stroke Registry, which includes consecutive patients with acute cerebrovascular events admitted to Swiss Stroke Units and Stroke Centers. A linear model was fitted to the weekly admission from 2018 and 2019 and was used to quantify deviations from the expected weekly admissions from 13 March to 26 April 2020 (the "lockdown period"). Characteristics and 3-month outcome of patients admitted during the lockdown period were compared with patients admitted during the same calendar period of 2018 and 2019.
Results: In all, 28,310 patients admitted between 1 January 2018 and 26 April 2020 were included. Of these, 4491 (15.9%) were admitted in the periods March 13-April 26 of the years 2018-2020. During the lockdown in 2020, the weekly admissions dropped by up to 22% compared to rates expected from 2018 and 2019. During three consecutive weeks, weekly admissions fell below the 5% quantile (likelihood 0.38%). The proportion of intracerebral hemorrhage amongst all registered admissions increased from 7.1% to 9.3% (p = 0.006), and numerically less severe strokes were observed (median National Institutes of Health Stroke Scale from 3 to 2, p = 0.07).
Conclusions: Admissions and clinical severity of acute cerebrovascular events decreased substantially during the lockdown in Switzerland. Delivery and quality of acute stroke care were maintained.
Keywords: COVID-19; epidemiology; stroke.
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Conflict of interest statement
GMDM has been receiving support from the Swiss National Science Foundation (No. 32003B_200573, No. PBBEP3_139388); Spezialprogramm Nachwuchsförderung Klinische Forschung, University of Basel; Science Funds (Wissenschaftspool) of the University Hospital Basel; Swiss Heart Foundation; Bangerter‐Rhyner‐Stiftung; Swisslife Jubiläumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr Ettore Balli; De Quervain research grant; Thermo Fisher GmbH; travel honoraria by Bayer and BMS/Pfizer; speaker honoraria by Bayer and Medtronic. He is a member of the Steering Committee of PACIFIC Stroke (NCT04304508). Industry payments are made to the research fund of the University Hospital Basel. PM reports receipt of research support from Siemens, Cerenovus, iSchmaview, Medtronic, Stryker, the Swiss Heart Foundation and the Swiss National Foundation, receipt of consultant fees paid to the institution from Medtronic, Cerenovus, Phenox and Microvention during the conduct of the study, unrelated to the submitted work. FM has been receiving support from the Swiss Heart Foundation. All other authors report no disclosures related to the present paper.
Figures


References
-
- Epidemiologische Zwischenbilanz zum neuen . Coronavirus in der Schweiz und im Fürstentum Liechtenstein. Accessed July 22, 2021. https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche‐epidemien‐pa...
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous